Tapping the untapped: type II L-asparaginase from marine crustacean-derived Chryseomicrobium amylolyticum as a potential bio better for blood cancer therapy.

ABSTRACT: L-asparaginase is a vital antineoplastic drug. The side effects of the current formulations intrigued researchers to explore novel candidates. The study evaluated a novel type-II L-asparaginase from Chryseomicrobium amylolyticum from marine crab, Scylla serrata. Statistical optimization enhanced production to 281.6 from 115.69 IU/ml. The purified enzyme had 173.69 IU/mg protein specific activity. The Km, Vmax, and Kcat were 6.364 µM, 909.09 µM/min, and 222.82 /sec. The enzyme didn't react with L-glutamine, D-glutamine, L-glutamic acid, and urea, a clinically desirable feature. In vitro trypsin and serum half-life were ~ 39 h and ~ 27 min. The study enlisted ions, protein-modifying agents, and surfactants influencing its activity. The detailed in silico analyses of the functional gene predi

SUBMITTER: Lailaja VP 

PROVIDER: S-EPMC12287261 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature